Background/Aims: Vitamin D deficiency is common in children with neurodisabilities. Oral vitamin D3 may not be absorbed appropriately due to dysphagia and tube feeding. The aim of this study was to compare efficacy of vitamin D3 buccal spray with that of oral drops. Methods: Twenty-four children with neurodisabilities (5–17 years) and vitamin D deficiency (25(OH)D ≤20 ng/mL) were randomized to receive vitamin D3 buccal spray 800 IU/daily (n = 12) or oral drops 750 IU/daily (n = 12) for 3 months during winter. Results: Both groups had a significant increase in 25(OH)D (z = 150; p < 0.0001). The differences between baseline and final parathyroid hormone measurements did not reach significance in both groups. Markers of bone formation and resorption did not change significantly in both groups. The satisfaction with the formulation was significantly higher in the patients using spray. Conclusion: Vitamin D3 supplementation with buccal spray and oral drops are equally effective in short-term treatment of vitamin D deficiency in children with neurodisabilities. Buccal spray may be more acceptable by the patients.

1.
Holló A, Clemens Z, Lakatos P: Epilepsy and vitamin D. Int J Neurosci 2014; 124: 387–393.
2.
Shellhaas RA, Joshi SM: Vitamin D and bone health among children with epilepsy. Pediatr Neurol 2010; 42: 385–393.
3.
Menon B, Harinarayan CV: The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism – a longitudinal study. Seizure 2010; 19: 153–158.
4.
Salam R, Baruah MP, Kalra B: Way to bone health may be just under the tongue! Sublingual vitamin D. J Med Nutr Nutraceut 2014; 3: 12.
5.
Nibha PK, Pancholi SS: An overview on: sublingual route for systemic drug delivery. Int J Res Pharm Biomed Sci 2012; 3: 913–923.
6.
Satia MC, Mukim AG, Tibrewala KD, Bhavsar MS: A randomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption. Nutr J 2015; 14: 114.
7.
Rathbone MJ, Pather I, Senel S: Overview of oral mucosal delivery; in Rathbone MJ, Senel S, Pather I (eds): Oral Mucosal Drug Delivery and Therapy. Berlin, Springer, 2015, pp 17–29.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.